- Home
- TJGC vs ALGS Comparison
TJGC vs ALGS Comparison
Compare TJGC & ALGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TJGC | ALGS |
|---|---|---|
| Founded | 2022 | 2018 |
| Country | Hong Kong | United States |
| Employees | 19 | N/A |
| Industry | Advertising | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.4M | 37.1M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | TJGC | ALGS |
|---|---|---|
| Price | $1.68 | $6.42 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $39.33 |
| AVG Volume (30 Days) | 91.0K | ★ 209.4K |
| Earning Date | 08-14-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 88.30 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,186,000.00 |
| Revenue This Year | N/A | $32.20 |
| Revenue Next Year | N/A | $4.71 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.49 | $5.12 |
| 52 Week High | $1.85 | $13.69 |
Technical Indicators
Market Signals| Indicator | TJGC | ALGS |
|---|---|---|
| Relative Strength Index (RSI) | 61.72 | 46.06 |
| Support Level | $0.88 | $6.25 |
| Resistance Level | N/A | $8.30 |
| Average True Range (ATR) | 0.23 | 0.49 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 81.83 | 55.24 |
Price Performance
Historical ComparisonAbout TJGC TJGC Group Limited Ordinary Shares
TJGC Group Ltd, formerly CTRL Group Ltd is an integrated marketing and advertising services provider in Hong Kong specializing in mobile games promotion for the local market. It provide services to mobile game developers, principally developers of mobile gaming applications or apps that gamers download from the developers' websites and applicable mobile operating systems, such as Apple Store or Android Google Play Store.
About ALGS Aligos Therapeutics Inc.
Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.